Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Latest from Memorial Sloan Kettering Cancer Center

FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC

November 24, 2022

Dr Abou-Alfa discusses the FDA approval of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, the regimen’s unique mechanism of action, and the importance of expanding global access to this combination.

Selpercatinib Approval in RET Fusion+ Solid Tumors Expands Tumor-Agnostic Feasibility

November 23, 2022

Alexander Drilon, MD, discusses key efficacy and safety data for selpercatinib from LIBRETTO-001, how the FDA approval of selpercatinib affects the current treatment landscape for RET fusion–positive advanced solid tumors, and ongoing research to expand the reach of tumor-agnostic drugs.

Dr. Lin on Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

November 16, 2022

Richard J. Lin, MD, PhD, discusses the manufacturing considerations that factor into the CAR T-cell decision-making process in diffuse large B-cell lymphoma, the importance of open communication between community and referral physicians, and how early referral leads to optimal patient outcomes with CAR T-cell therapy.

Frontline Setting Boasts Multiple Treatment Options for Patients With ALL

November 09, 2022

Clinicians treating patients with newly diagnosed acute lymphocytic leukemia now have multiple options at their disposal, including tyrosine kinase inhibitors, blinatumomab, and multiagent chemotherapy-based regimens, with more options aiming to enter the treatment paradigm.